Drugs / Human papillomavirus (HPV) vaccine, 9-valent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06624839 | Mar 2025 → Jan 2027 expected | HIV infectious disease, anus disorder, human papilloma virus infection | University of Maryland, Baltimore | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human papillomavirus (HPV) vaccine, 9-valent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06624839 ↗ |
| Known as | Gardasil9 | “assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or...” NCT06624839 ↗ |
| Modality | Vaccine | “the 9-valent human papillomavirus (HPV) recombinant vaccine” NCT06624839 ↗ |
| Route | Intramuscular | “0.5 ml intramuscular injection” NCT06624839 ↗ |